Kahalalide F, an antitumor depsipeptide in clinical trials, and its analogues as effective antileishmanial agents

Molecular Pharmaceutics

Volumn 6, Issue 3, 2009, Pages 813-824

  Cruz, Luis J ^a   Luque Ortega, Juan R ^b   Rivas, Luis ^b   Albericio, Fernando ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

Author keywords

Combinatorial chemistry; Kahalalide F; Leishmania; Marine compound; Membrane permeabilization; Solid phase synthesis; Structure activity relationship

Indexed keywords

AMPHOTERICIN B; ANTILEISHMANIAL AGENT; DEPSIPEPTIDE; KAHALALIDE F; MILTEFOSINE;

ANIMAL CELL; ANTIPROTOZOAL ACTIVITY; ARTICLE; CELL MEMBRANE; CONTROLLED STUDY; DEPOLARIZATION; DRUG EFFICACY; DRUG MECHANISM; LEISHMANIA; LEISHMANIA DONOVANI; LEISHMANIA PIFANOI; MEMBRANE PERMEABILITY; MOUSE; NONHUMAN; PARASITE; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; TRANSMISSION ELECTRON MICROSCOPY;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTIPROTOZOAL AGENTS; CELL MEMBRANE; CELLS, CULTURED; CLINICAL TRIALS AS TOPIC; DEPSIPEPTIDES; LEISHMANIA; LEISHMANIASIS; MEMBRANE POTENTIALS; MICE; MICE, INBRED BALB C; MICROSCOPY, ELECTRON, TRANSMISSION; MOLECULAR STRUCTURE;

EID: 67249165802     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp8001039     Document Type: Article

References (53)

1. Chappuis, F.; Sundar, S.; Hailu, A.; Ghalib, H.; Rijal, S.; Peeling, R. W.; Alvar, J.; Boelaert, M. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control. Nat. Rev. Microbiol. 2007, 5, 873-882.
2. World Health Organization. http://www.who.int/leishmaniasis/ burden/en/.
3. Loiseau, P. M.; Bories, C. Mechanisms of drug action and drug resistance in Leishmania as basis for therapeutic target identification and design of antileishmanial modulators. Curr. Top. Med. Chem. 2006, 6, 539-550.
4. Croft, S. L.; Sundar, S.; Fairlamb, A. H. Drug resistance in leishmaniasis. Clin. Microbiol. Rev. 2006, 19, 111-126.
5. Fuertes, M. A.; Nguewa, P. A.; Castilla, J.; Alonso, C.; Perez, J. M. Anticancer compounds as leishmanicidal drugs: challenges in chemotherapy and future perspectives. Curr. Med. Chem. 2008, 15, 433-439.
6. Golenser, J.; Domb, A. New formulations and derivatives of amphotericin B for treatment of leishmaniasis. Mini-Rev. Med. Chem. 2006, 6, 153-162.
7. de Castro, S. L.; Santa-Rita, R. M.; Urbina, J. A.; Croft, S. L. Antiprotozoal lysophospholipid analogues: a comparison of their activity against trypanosomatid parasites and tumor cells. Mini- Rev. Med. Chem. 2004, 4, 141-151.
8. Rossi, L. M.; Rangasamy, P.; Zhang, J.; Qiu, X. Q.; Wu, G. Y. Research advances in the development of peptide antibiotics. J. Pharm. Sci. 2008, 97, 1060-1070.
9. Guerrero, E.; Saugar, J. M.; Matsuzaki, K.; Rivas, L. Role of positional hydrophobicity in the leishmanicidal activity of magainin 2. Antimicrob. Agents Chemother. 2004, 48, 2980-2986.
10. Luque-Ortega, J. R.; Van't Hof, W.; Veerman, E. C.; Saugar, J. M.; Rivas, L. Human antimicrobial peptide histatin 5 is a cellpenetrating peptide targeting mitochondrial ATP synthesis in. Leishmania. FASEB J. 2008, 22, 1817-1828.
11. Mangoni, M. L.; Papo, N.; Saugar, J. M.; Barra, D.; Shai, Y.; Simmaco, M.; Rivas, L. Effect of natural L- to D-amino acid conversion on the organization, membrane binding, and biological function of the antimicrobial peptides bombinins H. Biochemistry 2006, 45, 4266-4276.
12. Alberola, J.; Rodriguez, A.; Francino, O.; Roura, X.; Rivas, L.; Andreu, D. Safety and efficacy of antimicrobial peptides against naturally acquired leishmaniasis. Antimicrob. Agents Chemother. 2004, 48, 641-643.
13. Jimeno, J.; Aracil, M.; Tercero, J. C. Adding pharmacogenomics to the development of new marine-derived anticancer agents. J. Transl. Med. 2006, 4, 3.
14. Rawat, D. S.; Joshi, M. C.; Joshi, P.; Atheaya, H. Marine peptides and related compounds in clinical trial. Anticancer Agents Med. Chem. 2006, 6, 33-40.
15. Scheinfeld, N. A comparison of available and investigational antibiotics for complicated skin infections and treatment-resistant Staphylococcus aureus and Enterococcus. J. Drugs Dermatol. 2007, 6, 97-103.
16. Shih, C.; Teicher, B. A. Cryptophycins: a novel class of potent antimitotic antitumor depsipeptides. Curr. Pharm. Des. 2001, 7, 1259-1276.
17. Hamann, M. T.; Scheuer, P. J. Kahalalide-Fsa Bioactive depsipeptide from the Sacoglossan mollusk Elysia rufescens and the green-alga Bryopsis sp. J. Am. Chem. Soc. 1993, 115, 5825-5826.
18. Hamann, M. T. Technology evaluation: Kahalalide F, PharmaMar. Curr. Opin. Mol. Ther. 2004, 6, 657-665.
19. Faircloth, G.; Cuevas, C. Kahalalide F and ES285: potent anticancer agents from marine molluscs. Prog. Mol. Subcell. Biol. 2006, 43, 363-379.
20. Suárez, Y.; González, L.; Cuadrado, A.; Berciano, M.; Lafarga, M.; Muñoz, A. Kahalalide F, a new marine-derived compound, induces oncosis in human prostate and breast cancer cells. Mol. Cancer Ther. 2003, 2, 863-872.
21. Sewell, J. M.; Mayer, I.; Langdon, S. P.; Smyth, J. F.; Jodrell, D. I.; Guichard, S. M. The mechanism of action of Kahalalide F: variable cell permeability in human hepatoma cell lines. Eur. J. Cancer 2005, 41, 1637-1644. (Pubitemid 40981847)
22. García-Rocha, M.; Bonay, P.; Avila, J. The antitumoral compound Kahalalide F acts on cell lysosomes. Cancer Lett. 1996, 99, 43-50. (Pubitemid 26031079)
23. Shilabin, A. G.; Kasanah, N.; Wedge, D. E.; Hamann, M. T. Lysosome and HER3 (ErbB3) selective anticancer agent kahalalide F: semisynthetic modifications and antifungal lead-exploration studies. J. Med. Chem. 2007, 50, 4340-4350.
24. Janmaat, M. L.; Rodríguez, J. A.; Jimeno, J.; Kruyt, F. A.; Giaccone, G. Kahalalide F induces necrosis-like cell death that involves depletion of ErbB3 and inhibition of Akt signaling. Mol. Pharmacol. 2005, 68, 502-510.
25. Piggott, A. M.; Karuso, P. Rapid identification of a protein binding partner for the marine natural product kahalalide F by using reverse chemical proteomics. ChemBioChem 2008, 9 (4), 524-530.
26. Hill, R. T.; Hamann, M. T.; Enticknap, J.; Rao, K., V. Kahalalide-producing bacteria and methods of identifying kahalalide-producing bacteria and preparing kahalalides. PCT Int. Appl. 2005, WO2005042720.
27. Gracia, C.; Isidro-Llobet, A.; Cruz, L. J.; Acosta, G. A.; Alvarez, M.; Cuevas, C.; Giralt, E.; Albericio, F. Convergent approaches for the synthesis of the antitumoral peptide, Kahalalide F. Study of orthogonal protecting groups. J. Org. Chem. 2006, 71, 7196-7204.
28. López-Macià, A.; Jiménez, J. C.; Royo, M.; Giralt, E.; Albericio, F. Synthesis and structure determination of kahalalide F (1,2). J. Am. Chem. Soc. 2001, 123, 11398-11401.
29. Jiménez, J. C.; López-Macià, A.; Gracia, C.; Varón, S.; Carrascal, M.; Caba, J. C.; Royo, M.; Francesc, A. M.; Cuevas, C.; Giralt, E.; Albericio, F. Structure-activity relationship of kahalalide F synthetic analogues. J. Med. Chem. 2008, 51, 4920-4931.
30. Luque-Ortega, J. R.; Saugar, J. M.; Chiva, C.; Andreu, D.; Rivas, L. Identification of new leishmanicidal peptide lead structures by automated real-time monitoring of changes in intracellular ATP. Biochem. J. 2003, 375, 221-230.s (Pubitemid 37255399)
31. Díaz-Achirica, P.; Ubach, J.; Guinea, A.; Andreu, D.; Rivas, L. The plasma membrane of Leishmania donovani promastigotes is the main target for CA(1-8)M(1-18), a synthetic cecropin A-melittin hybrid peptide. Biochem. J. 1998, 330, 453-460.
32. Jimeno, J.; Faircloth, G.; Fernández Sousa-Faro, J. M.; Scheuer, P.; Rinehart, K. New Marine Derived Anticancer Therapeutics - A Journey from the Sea to Clinical Trials. Marine Drugs 2004, 2, 14-19.
33. Rodríguez-Mias, R. A.; Jiménez-García, J. C.; Gracia, C.; Kogan, M. J.; Albericio, F.; Giralt, E. Kahalalide F structural characterization in membrane mimicking environments and its implications to antitumoral activity. Submitted for publication.
34. Bonnard, I.; Manzanares, I.; Rinehart, K. L. Stereochemistry of kahalalide F. J. Nat. Prod. 2003, 66, 1466-1470.
35. Kondejewski, L. H.; Jelokhani-Niaraki, M.; Farmer, S. W.; Lix, B.; Kay, C. M.; Sykes, B. D.; Hancock, R. E.; Hodges, R. S. Dissociation of antimicrobial and hemolytic activities in cyclic peptide diastereomers by systematic alterations in amphipathicity. J. Biol. Chem. 1999, 274, 13181-13192.
36. Lee, D. L.; Powers, J. P.; Pflegerl, K.; Vasil, M. L.; Hancock, R. E. W.; Hodges, R. S. Effects of single D-amino acid substitutions on disruption of beta-sheet structure and hydrophobicity in cyclic 14-residue antimicrobial peptide analogs related to gramicidin S. J. Pept. Res 2004, 63, 69-84. (Pubitemid 38333836)
37. Oren, Z.; Shai, Y. Selective lysis of bacteria but not mammalian cells by diastereomers of melittin: structure-function study. Biochemistry 1997, 36, 1826-1835. (Pubitemid 27086279)
38. Papo, N.; Oren, Z.; Pag, U.; Sahl, H. G.; Shai, Y. The consequence of sequence alteration of an amphipathic R-helical antimicrobial peptide and its diastereomers. J. Biol. Chem. 2002, 277, 33913-33921.
39. Kraus, D.; Peschel, A. Molecular mechanisms of bacterial resistance to antimicrobial peptides. Curr. Top. Microbiol. Immunol. 2006, 306, 231-250.
40. Ran, S.; Downes, A.; Thorpe, P. E. Increased exposure of anionic phospholipids on the surface of tumor blood vessels. Cancer Res. 2002, 62, 6132-6140. (Pubitemid 35244462)
41. Schroder-Borm, H.; Bakalova, R.; Andra, J. The NK-lysin derived peptide NK-2 preferentially kills cancer cells with increased surface levels of negatively charged phosphatidylserine. FEBS Lett. 2005, 579, 6128-6134. (Pubitemid 41546259)
42. Shai, Y.; Oren, Z. From "carpet" mechanism to de-novo designed diastereomeric cell-selective antimicrobial peptides. Peptides 2001, 22, 1629-1641.
43. Radzishevsky, I. S.; Rotem, S.; Zaknoon, F.; Gaidukov, L.; Dagan, A.; Mor, A. Effects of acyl versus aminoacyl conjugation on the properties of antimicrobial peptides. Antimicrob. Agents Chemother. 2005, 49, 2412-2420.
44. Gaidukov, L.; Fish, A.; Mor, A. Analysis of membrane-binding properties of dermaseptin analogues: relationships between binding and cytotoxicity. Biochemistry 2003, 42, 12866-12874. (Pubitemid 37385817)
45. Chicharro, C.; Granata, C.; Lozano, R.; Andreu, D.; Rivas, L. N-terminal fatty acid substitution increases the leishmanicidal activity of CA(1-7)M(2-9), a cecropin-melittin hybrid peptide. Antimicrob. Agents Chemother. 2001, 45, 2441-2449.
46. Mangoni, M. L.; Marcellini, H. G.; Simmaco, M. Biological characterization and modes of action of temporins and bombinins H, multiple forms of short and mildly cationic anti-microbial peptides from amphibian skin. J. Pept. Sci. 2007, 13, 603-613
47. Van Hellemond, J. J.; Tielens, A. G. Inhibition of the respiratory chain results in a reversible metabolic arrest in Leishmania promastigotes. Mol. Biochem. Parasitol. 1997, 85, 135-138.
48. Suárez, Y.; González, L.; Cuadrado, A.; Berciano, M.; Lafarga, M.; Muñoz, A. Kahalalide F, a new marine-derived compound, induces oncosis in human prostate and breast cancer cells. Mol. Cancer Ther. 2003, 2, 863-872.
49. Pupkis, M. F.; Tetley, L.; Coombs, G. H. Leishmania mexicana: amastigote hydrolases in unusual lysosomes. Exp. Parasitol. 1986, 62, 29-39.
50. Luque-Ortega, J. R.; Rivas, L. Miltefosine (hexadecylphosphocholine) inhibits cytochrome c oxidase in Leishmania donovani promastigotes. Antimicrob. Agents Chemother. 2007, 51, 1327-1332.
51. Brown, A. P.; Morrissey, R. L.; Faircloth, G. T.; Levine, B. S. Preclinical toxicity studies of kahalalide F, a new anticancer agent: single and multiple dosing regimens in the rat. Cancer Chemother. Pharmacol 2002, 50, 333-340.
52. Jimeno, J.; López-Martín, J. A.; Ruiz-Casado, A.; Izquierdo, M. A.; Scheuer, P. J.; Rinehart, K. Progress in the clinical development of new marine-derived anticancer compounds. Anticancer Drugs 2004, 15, 321-329. (Pubitemid 38526755)
53. Rademaker-Lakhai, J. M.; Horenblas, S.; Meinhardt, W.; Stokvis, E.; de Reijke, T. M.; Jimeno, J. M.; López-Lázaro, L.; López Martín, J. A.; Beijnen, J. H.; Schellens, J. H. Phase I clinical and pharmacokinetic study of kahalalide F in patients with advanced androgen refractory prostate cancer. Clin. Cancer Res. 2005, 11, 1854-1862.